What have we learned about randomized, controlled trials in neonatal sepsis?

Pediatric Critical Care Medicine

Volumn 6, Issue 3 SUPPL., 2005, Pages

  Tarnow Mordi, William O ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Controlled trials; Neonatal sepsis; Prospective meta analysis; Randomized

Indexed keywords

ANALYTICAL ERROR; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; INDIVIDUALIZATION; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; NEWBORN; NEWBORN CARE; NEWBORN MORTALITY; NEWBORN SEPSIS; OUTCOMES RESEARCH; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; REVIEW; SAMPLE SIZE; SURVIVAL; TREATMENT OUTCOME;

CRITICAL ILLNESS; HUMANS; INFANT, NEWBORN; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; SEPSIS; TREATMENT OUTCOME;

EID: 19444364851     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000161576.09029.56     Document Type: Review

References (30)

1. Cohen J, Guyatt G, Bernard GR, et al: New strategies for clinical trials in patients with sepsis and septic shock: UK Medical Research Council International Working Party. Crit Care Med 2001; 29:880-886
2. Randolph AG, Lacroix J: Randomized clinical trials in pediatric critical care: Rarely done but desperately needed. Pediatr Crit Care Med 2002; 3:102-106
3. Crowley P, Chalmers I, Keirse MJ: The effects of corticosteroid administration before preterm delivery: An overview of the evidence from controlled trials. Br J Obstet Gynaecol 1990; 97:11-25
4. Peto R, Baigent C: Trials: The next 50 years. Large scale randomised evidence of moderate benefits. BMJ 1998; 317:1170-1171
5. Pogue J, Yusuf S: Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351:47-52
6. Zhang B, Schmidt B: Do we measure the right end points? A systematic review of primary outcomes in recent neonatal randomized clinical trials. J Pediatr 2001; 138:76-80
7. Sinclair JC, Haughton DE, Bracken MB, et al: Cochrane neonatal systematic reviews: A survey of the evidence for neonatal therapies. Clin Perinatol 2003; 30:285-304
8. Yusuf S, Collins R, Peto R: Why do we need some large, simple randomized trials? Stat Med 1984; 3:409-422
9. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2:57-66
10. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-360
11. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339: 753-770
12. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345:669-685
13. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569-1581
14. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349:1641-1649
15. Chen ZM, Sandercock P, Pan HC, et al: Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31:1240-1249
16. Roberts I, Yates D, Sandercock P, et al: Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH trial): Randomized placebo-controlled trial. CRASH trial collaborators. Lancet 2004; 364:1321-1328
17. Altman D, Carroli G, Duley L, et al: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet 2002; 359:1877-1890
18. Kenyon SL, Taylor DJ, Tarnow-Mordi W: Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: The ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001; 357:979-988
19. Kenyon SL, Taylor DJ, Tarnow-Mordi W: Broad-spectrum antibiotics for spontaneous preterm labour: The ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001; 357:989-994
20. Kenyon S, Boulvain M, Neilson J: Antibiotics for preterm rupture of the membranes: A systematic review. Obstet Gynecol 2004; 104: 1051-1057
21. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995; 345:143-148
22. Vora A: Acute lymphoblastic leukemia: Optimizing treatment strategies in children. Paediatr Drugs 2002; 4:405-416
23. Yusuf S: Challenges in the conduct and interpretation of phase II (pilot) randomized trials. Am Heart J 2000; 139:S136-S142
24. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction: Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397-402
25. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945
26. Strippoli GF, Craig M, Deeks JJ, et al: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ 2004; 329:828
27. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. OPTIMIST Trial Study Group. JAMA 2003; 290:238-247
28. Pocock S, White I: Trials stopped early: Too good to be true? Lancet 1999; 353:943-944
29. Simes RJ: Prospective meta-analysis of cholesterol-lowering studies: The Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration. J Cardiol 1995; 76:122C-126C
30. Simes J, Furberg CD, Braunwald E, et al: Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: The Prospective Pravastatin Pooling project. Eur Heart J 2002; 23:207-215